Acute Myeloid Leukemia (AML)

Dr. Amy Duffield

Institution
Mount Sinai Medical Center
Physician Status
available for consultation
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Dr. Duffield is a board-certified hematopathologist, specializing in the diagnosis of cancers that arise in the bone marrow and lymphoid tissues. She completed a pathology residency and hematopathology fellowship at the Johns Hopkins Hospital and joined the faculty of Johns Hopkins in 2010. In 2020, she joined Memorial-Sloan Kettering to become a member of the Hematopathology Service.

Constandina Herbert, MN, RN, BMTCN

Institution
Fred Hutchinson Cancer Research Center
Physician Status
available for consultation
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Constandina Herbert, MN, RN, BMTCN is the Nursing Supervisor, Blood and Marrow Transplant Clinic at the Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center. Ms. Herbert works with patients, families, and caregivers as they navigate the transplant process.

Alrizomadlin (APG-115)

Alrizomadlin is an orally administered, selective, small-molecule inhibitor of the MDM2 protein. Alrizomadlin has strong binding affinity to MDM2 and is designed to activate tumor suppression activity of p53 by blocking the MDM2-p53 protein-protein interaction.

Anna Halpern, MD

Institution
Fred Hutchinson Cancer Research Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
I am both a hematologist-oncologist and a clinical researcher. Along with caring for you, I conduct research focused on hematologic (blood-based) malignancies — specifically, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), polycythemia vera, essential thrombocythemia and myelofibrosis. My overarching research aim is to help adults with these diseases have better outcomes by developing and testing evidence-based therapies that are tailored to your unique needs as a patient. I design and conduct clinical trials testing novel care concepts for people with AML and MDS, and I use

Kanwaldeep Mallhi, MD

Institution
Roswell Park Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
About
Dr. Kanwaldeep Mallhi is a pediatric oncologist and hematologist who specializes in nonmalignant blood disorders in children. These disorders include immunodeficiencies, bone marrow failure and metabolic errors. She is an expert in pediatric blood stem cell transplants, and her research focuses on alternative donor sources and the development of reduced-intensity conditioning regimens, which use radiation, chemotherapy or other procedures to remove diseased or failing cells prior to transplant.

Researchers Uncover How MN1 Overexpression Causes AML

Original Publication Date
Article Source
External Web Content
Meningioma-1 (MN1) is a protein whose overexpression has been linked to acute myeloid leukemia (AML) and brain tumors, and 70% to 80% of AML patients with high overexpression of MN1 die within two years. Yet the mechanism by which MN1 causes these diseases has largely remained a…

RARA Agonist Plus Azacitidine Shows Encouraging Activity in Relapsed/Refractory AML

Original Publication Date
Article Source
External Web Content
The novel agentSY-1425 combined with azacitidine appears to be active in retinoic acid receptor alpha (RARA) superenhancer–positive newly diagnosed and relapsed or refractory acute myeloid leukemia (AML), according to the results of a phase II trial presented at the 2020 American…

Nathan Punwani, MD, MPH

Institution
Cedars-Sinai
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
About
Dr. Punwani is a hematologist/oncologist with the Blood and Marrow Transplant Program at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai. He earned his BA from Lehigh University, an MPH in Health Care Management & Policy from Harvard School of Public Health and his MD from Drexel University College of Medicine. He did his Internal Medicine Residency at George Washington Unviersity Hospital and his Fellowships in Hematology and Oncology at the University of Southern California. Dr. Punwani is board certified in Internal Medicine and is both researcher and clinician with more

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.